5-Amino-1MQ / Study library
Filter by study model, then open the original record to examine methods and findings.
3 studies shown
The investigators identified quinolinium compounds with low-micromolar NNMT inhibition and related chemical features to measured activity. Docking supplied a proposed explanation for interactions at the substrate-binding site.
Reading limit: These assays characterize compound-target interactions. They do not establish an effective or safe human intervention.
An eleven-day mouse proof-of-concept experiment reported lower body weight and adipose measurements after 5-amino-1MQ exposure. Supporting cell work examined permeability, selectivity, and metabolic changes.
Reading limit: The experiment was short and used a specific animal model and formulation. It cannot establish sustained human weight change or long-term safety.
Researchers reported less weight and fat-mass gain and changes in glucose tolerance, insulin-related measures, and liver outcomes. They also measured exposure and tissue distribution.
Reading limit: These are preclinical outcomes. They do not validate a human treatment claim or show equivalence between commercial preparations.
We reviewed the linked primary publications and source records for the claims summarized here. This is a focused educational selection, not a systematic review or a clinical recommendation. Scientific findings are kept separate from supplier catalog descriptions.
Research findings apply to the exact compound, formulation, population and endpoints tested. They do not establish the identity, quality, clinical suitability or performance of a supplier’s product. This reference provides no dosing or administration guidance.
Confirm molecular identity, batch identification, analytical methods and the actual formulation before relating a commercial material to a publication. A purity percentage alone does not establish all of those facts.
Visit Disguised Alpha or read the extended compound profile.
